Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Leriglitazone

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Minoryx and Neuraxpharm team to provide new therapy for rare CNS disorders
    Minoryx and Neuraxpharm team to provide new therapy for rare CNS disorders

    10 Nov 2022

    // EUROPEANPHARMACEUTICALREVIEW

    https://www.europeanpharmaceuticalreview.com/news/176282/minoryx-and-neuraxpharm-therapy-for-rare-cns-disorders/

    EUROPEANPHARMACEUTICALREVIEW
    10 Nov 2022
    Share Share
    Minoryx‘s marketing authorization application for lead candidate leriglitazone
    Minoryx‘s marketing authorization application for lead candidate leriglitazone

    20 Sep 2022

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2022-09-20/minoryx-s-marketing-authorization-application-for-its-lead-candidate-leriglitazone-validated-by-ema-for-orphan-indication-x-linked-adrenoleukodystrophy-x-ald

    PHARMIWEB
    20 Sep 2022
    Share Share
    Minoryx presents topline results from Ph2/3 “ADVANCE” study significant
    Minoryx presents topline results from Ph2/3 “ADVANCE” study significant

    26 Jan 2021

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2021-01-26/minoryx-presents-topline-results-from-phase-23-advance-study-demonstrating-significant-clinical-benefit-of-leriglitazone-in-adrenomyeloneuropathy

    PHARMIWEB
    26 Jan 2021
    Share Share
    EIB provides Minoryx with up to €25 million to support development
    EIB provides Minoryx with up to €25 million to support development

    30 Oct 2020

    // EIB

    https://www.eib.org/en/press/all/2020-296-eib-provides-minoryx-with-up-to-eur25-million-to-support-development-of-breakthrough-therapies-in-orphan-neurodegenerative-diseases

    EIB
    30 Oct 2020
    Share Share
    Minoryx & Sperogenix to develop and commercialize leriglitazone
    Minoryx & Sperogenix to develop and commercialize leriglitazone

    22 Sep 2020

    // PRNASIA

    https://en.prnasia.com/releases/global/minoryx-therapeutics-and-sperogenix-therapeutics-enter-into-an-exclusive-license-agreement-to-develop-and-commercialize-leriglitazone-in-mainland-china-hong-kong-and-macau-292572.shtml

    PRNASIA
    22 Sep 2020
    Share Share